Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)

Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday,
October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical
Pain Drug Ketotransdel(R)

LA JOLLA, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals,
Inc. (OTC Bulletin Board: TDLP) today announced that it will host a conference
call and audio webcast on Tuesday, October 6, 2009 at 9:00 am, eastern, to
announce the top-line results of its Phase 3 clinical study for Ketotransdel®,
a topical cream based non-steroidal anti-inflammatory drug ("NSAID") for acute
pain. A press release will be issued on Tuesday, October 6, 2009 at 7:30 am,
eastern.

To participate in the call, dial 888-695-0608, or outside of the U.S., dial
719-457-2615, confirmation code 4282348 shortly before 9:00 am, eastern. The
audio webcast can be accessed via the Internet by visiting the Investor
Relations section of the Company's Web site at http://www.transdelpharma.com.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical
company developing non-invasive, topically delivered products. The Company's
innovative-patented Transdel(TM) cream formulation technology is designed to
facilitate the effective penetration of a variety of products through the
tough skin barrier. Ketotransdel®, the Company's lead pain product, utilizes
the Transdel technology to deliver the active drug, ketoprofen, a
non-steroidal anti-inflammatory drug through the skin directly into the
underlying tissues where the drug exerts its well-known anti-inflammatory and
analgesic effects. The Company intends to leverage its Transdel(TM) platform
technology to expand and create a portfolio of topical products for a variety
of indications. The Company is actively pursuing partnerships with companies
to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical
products. In June 2009, the Company announced that it entered into a license
agreement with JH Direct, LLC for the exclusive worldwide rights to Transdel's
anti-cellulite cosmeceutical product which utilizes the Company's Transdel(TM)
technology. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute
forward-looking statements. Forward-looking statements can be identified by
the use of words such as "expects," "plans," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning. Please note that forward-looking statements are based on
projections, that these projections involve judgment, and that individual
judgments may vary. Moreover, these statements are subject to risks and
uncertainties that cannot be predicted or quantified and consequently, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with the uncertainty of the
Company's future financial results and its ability to raise additional funds
to support its operations, its ability to complete the required clinical
trials and obtain FDA approval for Ketotransdel, the efficacy and the
commercial success of any products it develops, the impact of competitive
products or pricing, and technological changes. More detailed information
about the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K
and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may
be read free of charge on the SEC's web site at www.sec.gov. All
forward-looking statements included in this release are made as of the date of
this press release, and the Company assumes no obligation to update any such
forward-looking statements.

SOURCE Transdel Pharmaceuticals, Inc.

John Lomoro, CFO of Transdel Pharmaceuticals, Inc., +1-858-457-5300,
johnl@transdelpharma.com; or Investors, Rhonda Chiger of Rx Communications
Group, LLC, +1-917-322-2569, rchiger@rxir.com, or Media, Maureen Suda of Suda
Communications L.L.C., +1-585-387-9248, maureen_suda@yahoo.com, both for
Transdel Pharmaceuticals, Inc.